Reviewing XORTX Therapeutics (XRTX) & The Competition

XORTX Therapeutics (NASDAQ:XRTX) is one of 247 public companies in the “MED – DRUGS” industry, but how does it contrast to its competitors? We will compare XORTX Therapeutics to related companies based on the strength of its profitability, analyst recommendations, dividends, institutional ownership, risk, valuation and earnings.

Profitability

This table compares XORTX Therapeutics and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
XORTX Therapeutics	N/A	-120.32%	-90.53%
XORTX Therapeutics Competitors	-22,657.13%	-141.40%	-22.30%

Institutional & Insider Ownership

0.2% of XORTX Therapeutics shares are held by institutional investors. Comparatively, 43.9% of shares of all “MED – DRUGS” companies are held by institutional investors. 6.9% of XORTX Therapeutics shares are held by company insiders. Comparatively, 13.2% of shares of all “MED – DRUGS” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Earnings & Valuation

This table compares XORTX Therapeutics and its competitors gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
XORTX Therapeutics	N/A	-$2.66 million	-0.72
XORTX Therapeutics Competitors	$1.20 billion	$101.47 million	-4.48

XORTX Therapeutics’ competitors have higher revenue and earnings than XORTX Therapeutics. XORTX Therapeutics is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Volatility & Risk

XORTX Therapeutics has a beta of 0.46, meaning that its share price is 54% less volatile than the S&P 500. Comparatively, XORTX Therapeutics’ competitors have a beta of -0.38, meaning that their average share price is 138% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and target prices for XORTX Therapeutics and its competitors, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XORTX Therapeutics	1	0	0	0	1.00
XORTX Therapeutics Competitors	2810	4034	10299	465	2.48

As a group, “MED – DRUGS” companies have a potential upside of 61.07%. Given XORTX Therapeutics’ competitors stronger consensus rating and higher probable upside, analysts clearly believe XORTX Therapeutics has less favorable growth aspects than its competitors.

Summary

XORTX Therapeutics competitors beat XORTX Therapeutics on 9 of the 13 factors compared.

XORTX Therapeutics Company Profile

Xyratex Ltd (Xyratex) is a provider of data storage technology, including modular solutions for the enterprise data storage industry and hard disk drive (HDD) capital equipment for the HDD industry. Xyratex operates in two segments: Networked Storage Solutions (NSS) and Storage Infrastructure (SI). Its NSS products are primarily HDD based data storage subsystems and solutions, which it provides to original equipment manufacturers. Its SI products consist of HDD manufacturing process equipment, which it sells directly to manufacturers of HDDs and their component suppliers. Its product and solution portfolio for the enterprise data storage industry includes storage enclosures, integrated application platforms and high performance computing (HPC) data storage solutions. In April 2014, Seagate Technology PLC completed the acquisition of Xyratex Ltd.